Fig. 1From: Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaKaplan–Meier curves for 1-year overall survival (OS) rates of different melanoma subtypes. Pretreated patients with a metastatic cutaneous melanoma (1-year OS rate: 38 %), b mucosal melanoma (1-year OS rate: 14 %), and c occult melanoma (1-year OS rate: 27 %). All patients received ipilimumab 3 mg/kgBack to article page